PFG Advisors Trims Stake in Eli Lilly and Company

Investment firm reduces holdings in pharmaceutical giant by over 73%

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

PFG Advisors, an investment management firm, has decreased its holdings in Eli Lilly and Company (NYSE: LLY) by 73.1% during the third quarter, according to a recent SEC filing. The firm now owns 7,268 shares of the pharmaceutical company's stock, valued at $5.55 million, down from 19,720 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative drug development. The reduction in PFG Advisors' stake could signal a shift in investor sentiment or portfolio rebalancing, potentially impacting the stock's performance.

The details

According to the SEC filing, PFG Advisors sold 19,720 shares of Eli Lilly during the third quarter, reducing its total holdings to 7,268 shares. The firm's remaining stake in the company is valued at $5.55 million. The move comes as Eli Lilly's stock has seen significant gains over the past year, rising from around $623 per share to over $1,100 per share.

  • PFG Advisors decreased its holdings in Eli Lilly during the 3rd quarter of 2026.

The players

PFG Advisors

An investment management firm that has reduced its stake in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company known for its innovative drug development.

Got photos? Submit your photos here. ›

The takeaway

The reduction in PFG Advisors' Eli Lilly holdings could signal a shift in investor sentiment or portfolio rebalancing, though the reasons behind the move are not entirely clear. Investors will likely continue to monitor Eli Lilly's stock performance and any further changes in institutional ownership.